Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 4, 2010, Pages 1443-1452

  Ba, Boubakar B ^a   Arpin, Corinne ^b   Nso, Branly Bikie Bi ^a   Dubois, Véronique ^b   Saux, Marie Claude ^a   Quentin, Claudine ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b University Victor Segalen   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; GLYCINE; LINEZOLID; RNA 23S;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIOSTASIS; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROCOCCUS FAECALIS; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; OPERON; PHENOTYPE; PRIORITY JOURNAL; SIMULATION; STAPHYLOCOCCUS AUREUS; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77950143758     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01022-09     Document Type: Article

References (58)

1. Allen, G. P., and B. C. Bierman. 2009. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium. Int. J. Antimicrob. Agents 34:21-24.
2. Ba, B. B., A. Bernard, A. Iliadis, C. Quentin, D. Ducint, R. Etienne, M. Fourtillan, I. Maachi-Guillot, and M. C. Saux. 2001. New approach for accurate simulation of human pharmacokinetics in an in vitro pharmacodynamic model: application to ciprofloxacin. J. Antimicrob. Chemother. 47: 223-227.
3. Ba, B. B., B. Bikie Bi Nso, C. Quentin, and M. C. Saux. 2007. Determination of linezolid in growth media by high-performance liquid chromatography with on-line extraction. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 854:104-108.
4. Barger, A., C. Fuhst, and B. Wiedemann. 2003. Pharmacological indices in antibiotic therapy. J. Antimicrob. Chemother. 52:893-898.
5. Besier, S., A. Ludwig, J. Zander, V. Brade, and T. A. Wichelhaus. 2008. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob. Agents Chemother. 52:1570-1572.
6. Boak, L. M., J. Li, C. R. Rayner, and R. L. Nation. 2007. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob. Agents Chemother. 51:1287-1292.
7. Bourgeois-Nicolaos, N., L. Massias, B. Couson, M. J. Butel, A. Andremont, and F. Doucet-Populaire. 2007. Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo. J. Infect. Dis. 195:1480-1488.
8. Bozdogan, B., and P. C. Appelbaum. 2004. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents 23:113-119.
9. Bozdogan, B., D. Esel, C. Whitener, F. A. Browne, and P. C. Appelbaum. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52:864-868.
10. Burkhardt, O., K. Borner, N. von der Höh, P. Köppe, M. W. Pletz, C. E. Nord, and H. Lode. 2002. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J. Antimicrob. Chemother. 50:707-712.
11. Chopra, I., A. J. O'Neill, and K. Miller. 2003. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist. Updat. 6:137-145.
12. Daurel, C., A. L. Prunier, F. Chau, L. Garry, R. Leclercq, and B. Fantin. 2007. Role of hypermutability on bacterial fitness and emergence of resistance in experimental osteomyelitis due to Staphylococcus aureus. FEMS Immunol. Med. Microbiol. 51:344-349.
13. Dehghanyar, P., C. Bürger, M. Zeitlinger, F. Islinger, F. Kovar, M. Müller, C. Kloft, and C. Joukhadar. 2005. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob. Agents Chemother. 49:2367-2371.
14. Denamur, E., S. Bonacorsi, A. Giraud, P. Duriez, F. Hilali, C. Amorin, E. Bingen, A. Andremont, B. Picard, F. Taddei, and I. Matic. 2002. High frequency of mutator strains among human uropathogenic Escherichia coli isolates. J. Bacteriol. 184:605-609.
15. Diekema, D. J., and R. N. Jones. 2001. Oxazolidinone antibiotics. Lancet 358:1975-1982.
16. Ellner, P. D., and H. C. Neu. 1981. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA 246:1575-1578.
17. Firsov, A. A., S. N. Vostrov, A. A. Shevchenko, and G. Cornaglia. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287.
18. French, G. 2001. Linezolid. Int. J. Clin. Pract. 55:59-63.
19. Frimodt-Møller, N. 2002. How predictive is PK/PD for antibacterial agents? Int. J. Antimicrob. Agents 19:333-339.
20. Gee, T., R. Ellis, G. Marshall, J. Andrews, J. Ashby, and R. Wise. 2001. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother. 45:1843-1846.
21. Gonzales, R. D., P. C. Schreckenberger, M. B. Graham, S. Kelkar, K. DenBesten, and J. P. Quinn. 2001. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357:1179.
22. Huang, V., and M. J. Rybak. 2005. Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob. Agents Chemother. 49:302-308.
23. Jullin, J., et al. 2001. Prog. Abstr. 21st Interdisciplinary Meet. Anti-infect. Chemother., abstr. 127/P1, p. 131.
24. Kister, G., et al. 1998. Prog. Abstr. 2nd Sci. Meet. Assoc. Pharm. Faculties Pharmacologists, abstr. 13, p. 14.
25. Kloss, P., L. Xiong, D. L. Shinabarger, and A. S. Mankin. 1999. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J. Mol. Biol. 294:93-101.
26. LaPlante, K. L., S. N. Leonard, D. R. Andes, W. A. Craig, and M. J. Rybak. 2008. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob. Agents Chemother. 52:2156-2162.
27. LaPlante, K. L., and M. J. Rybak. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48:4665-4672.
28. LeClerc, J. E., B. Li, W. L. Payne, and T. A. Cebula. 1996. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 274: 1208-1211.
29. Lobritz, M., R. Hutton-Thomas, S. Marshall, and L. B. Rice. 2003. Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis. Antimicrob. Agents Chemother. 47: 3318-3320.
30. Louie, A., H. S. Heine, K. Kim, D. L. Brown, B. VanScoy, W. Liu, M. Kinzig-Schippers, F. Sorgel, and G. L. Drusano. 2008. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob. Agents Chemother. 52:2486-2496.
31. MacGowan, A., C. Rogers, H. A. Holt, M. Wootton, and K. Bowker. 2000. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin. J. Antimicrob. Chemother. 46:73-78.
32. MacGowan, A. P. 2003. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother. 51(Suppl. 2):ii, 17-25.
33. Marshall, S. H., C. J. Donskey, R. Hutton-Thomas, R. A. Salata, and L. B. Rice. 2002. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46:3334-3336.
34. Meka, V. G., S. K. Pillai, G. Sakoulas, C. Wennersten, L. Venkataraman, P. C. DeGirolami, G. M. Eliopoulos, R. C. Moellering, Jr., and H. S. Gold. 2004. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J. Infect. Dis. 190:311-317.
35. Mendes, R. E., L. M. Deshpande, M. Castanheira, J. DiPersio, M. A. Saubolle, and R. N. Jones. 2008. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52:2244-2246.
36. Mouton, J. W., M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601-607.
37. Muller, M., A. dela Pena, and H. Derendorf. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48:1441-1453.
38. O'Neill, A. J., and I. Chopra. 2002. Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low. J. Antimicrob. Chemother. 50:161-169.
39. Paulsen, I. T., L. Banerjei, G. S. A. Myers, K. E. Nelson, R. Seshadri, T. D. Read, D. E. Fouts, J. A. Eisen, S. R. Gill, J. F. Heidelberg, H. Tettelin, R. J. Dodson, L. Umayam, L. Brinkac, M. Beanan, S. Daugherty, R. T. DeBoy, S. Durkin, J. Kolonay, R. Madupu, W. Nelson, J. Vamathevan, B. Tran, J. Upton, T. Hansen, J. Shetty, H. Khouri, T. Utterback, D. Radune, K. A. Ketchum, B. A. Dougherty, and C. M. Fraser. 2003. Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science 299: 2071-2074.
40. Pillai, S. K., G. Sakoulas, C. Wennersten, G. M. Eliopoulos, R. C. Moellering, Jr., M. J. Ferraro, and H. S. Gold. 2002. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J. Infect. Dis. 186:1603-1607.
41. Prunier, A. L., and R. Leclercq. 2005. Role of mutS and mutL genes in hypermutability and recombination in Staphylococcus aureus. J. Bacteriol. 187:3455-3464.
42. Prunier, A. L., B. Malbruny, M. Laurans, J. Brouard, J. F. Duhamel, and R. Leclercq. 2003. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J. Infect. Dis. 187:1709-1716.
43. Prunier, A. L., B. Malbruny, D. Tandé, B. Picard, and R. Leclercq. 2002. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrob. Agents Chemother. 46:3054-3056.
44. Prystowsky, J., F. Siddiqui, J. Chosay, D. L. Shinabarger, J. Millichap, L. R. Peterson, and G. A. Noskin. 2001. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycinresistant enterococci. Antimicrob. Agents Chemother. 45:2154-2156.
45. Roberts, S. M., A. F. Freeman, S. M. Harrington, S. M. Holland, P. R. Murray, and A. M. Zelazny. 2006. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr. Infect. Dis. J. 25:562-564.
46. Sambrook, J., F. Fritsch, and T. Maniatis (ed.). 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
47. Schaaff, F., A. Reipert, and G. Bierbaum. 2002. An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 46:3540-3548.
48. Schumacher, A., R. Trittler, J. A. Bohnert, K. Kümmerer, J. M. Pagès, and W. V. Kern. 2007. Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation. J. Antimicrob. Chemother. 59:1261-1264.
49. Slatter, J. G., D. J. Stalker, K. L. Feenstra, I. R. Welshman, J. B. Bruss, J. P. Sams, M. G. Johnson, P. E. Sanders, M. J. Hauer, P. E. Fagerness, R. P. Stryd, G. W. Peng, and E. M. Shobe. 2001. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab. Dispos. 29:1136-1145.
50. Stein, G. E., S. Schooley, C. A. Peloquin, A. Missavage, and D. H. Havlichek. 2007. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J. Antimicrob. Chemother. 60:819-823.
51. Strukova, E. N., M. V. Smirnova, S. N. Vostrov, I. Y. Lubenko, A. A. Firsov, S. H. Zinner, and Y. A. Portnoy. 2009. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. Int. J. Antimicrob. Agents 33:251-254.
52. Tsiodras, S., H. S. Gold, G. Sakoulas, G. M. Eliopoulos, C. Wennersten, L. Venkataraman, R. C. Moellering, Jr., and M. J. Ferraro. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208.
53. Willems, R. J., J. Top., D. J. Smith, D. I. Roper, S. E. North, and N. Woodford. 2003. Mutations in the DNA mismatch repair proteins MutS and MutL of oxazolidinone-resistant or -susceptible Enterococcus faecium. Antimicrob. Agents Chemother. 47:3061-3066.
54. Wolter, N., A. M. Smith, D. J. Farrell, W. Schaffner, M. Moore, C. G. Whitney, J. H. Jorgensen, and K. P. Klugman. 2005. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob. Agents Chemother. 49:3554-3557.
55. Worth, L., Jr., T. Bader, J. Yang, and S. Clark. 1998. Role of MutS ATPase activity in MutS, L-dependent block of in vitro strand transfer. J. Biol. Chem. 273:23176-23182.
56. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl. 3):S147-S156.
57. Zinner, S. H., D. Gilbert, I. Y. Lubenko, K. Greer, and A. A. Firsov. 2008. Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline. J. Antimicrob. Chemother. 61:629-635.
58. Zurenko, G. E., B. H. Yagi, R. D. Schaadt, J. W. Allison, J. O. Kilburn, S. E. Glickman, D. K. Hutchinson, M. R. Barbachyn, and S. J. Brickner. 1996. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40:839-845.